CJC-1295 (No DAC) Buying Checklist for Labs (2026)

Standardizing Preclinical Procurement for CJC-1295 (No DAC)

CJC-1295 (No DAC)—also designated as Modified GRF 1-29—is a synthetic 29-amino-acid peptide derived from human growth hormone-releasing hormone (GHRH). In experimental research, CJC-1295 (No DAC) functions as a GHRH analog. Preclinical studies suggest that it binds to the GHRH receptor on anterior pituitary somatotropes, stimulating pulsatile growth hormone (GH) secretion. It is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, cellular regeneration models, and metabolic pathway mapping.

Because synthetic peptide manufacturing can yield incomplete sequences, truncated impurities, or residual solvent carryover, principal investigators must apply rigorous vendor evaluation frameworks. Failing to verify compound purity before initiating in vitro assays or animal models introduces unaccounted variables that invalidate biochemical data. This purchasing checklist provides laboratory managers with an objective methodology for evaluating suppliers, analytical documentation, and physical specifications when acquiring CJC-1295 (No DAC) for scientific research.

Item 1: Sequence Identity & Chemical Structure Verification

The first step in evaluating a vendor's catalog involves confirming the exact chemical identity and modification status of the peptide. Native GHRH 1-29 is susceptible to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). CJC-1295 (No DAC) incorporates specific amino acid substitutions at positions 2, 8, 15, and 27 (typically [D-Ala2, Gln8, Ala15, Leu27]-GHRH 1-29) to enhance enzymatic resistance while omitting the Drug Affinity Complex (DAC) maleimide moiety.

Before issuing a purchase order, procurement personnel must confirm that the vendor provides the precise chemical formula (C152H252N44O42) and a nominal molecular weight of approximately 3357.9 Da. Conflating CJC-1295 (No DAC) with native Sermorelin or conjugate-modified variants alters receptor binding kinetics and half-life parameters in experimental models. Research facilities should cross-reference product datasheets within the PX1 Research peptide library to verify sequence accuracy prior to purchase.

Item 2: Lot-Specific Certificate of Analysis (COA) Auditing

A primary marker of vendor integrity is the accessibility of lot-specific Certificate of Analysis (COA) documentation. Laboratories must avoid suppliers that display static, generalized, or out-of-date analytical reports. Every synthesis batch must undergo independent analysis, and the corresponding COA must match the exact lot number printed on the physical vial delivered to the lab.

Researchers should demand transparency regarding the testing facility. Valid COAs originate from independent, ISO/IEC 17025 accredited analytical laboratories located within the United States. You can review example documentation standards and verify testing methodologies via the PX1 COA verification portal to understand how lot-matched documentation should be formatted and validated.

Item 3: Analytical Purity Standards (HPLC & Mass Spectrometry)

Purity requirements for cell culture assays and animal studies should meet or exceed 98.0% as determined by High-Performance Liquid Chromatography (HPLC). When evaluating an HPLC chromatogram on a COA, verify the integration of the main peak relative to secondary peak areas. Minor peaks represent synthesis artifacts, deletion sequences, or truncated peptides that may inadvertently bind off-target receptors.

Complementing HPLC, Mass Spectrometry (MS)—typically Electrospray Ionization (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF)—is required to confirm molecular mass. The major observed mass peak must align with the theoretical mass within tight instrument tolerances. Vendors offering all research peptides should readily provide full-spectrum HPLC chromatograms and mass spectra rather than summary scorecards.

Item 4: Endotoxin Thresholds and Bioburden Controls

Bacterial endotoxins (lipopolysaccharides) present a major confounding factor in cell culture systems and in vivo animal models. High endotoxin exposure can trigger inflammatory signaling pathways, altering cytokine profiles, receptor expression, and cellular viability independent of the target compound's biological activity.

In vitro data indicate that research peptides intended for sensitive cell line treatments or animal models must adhere to strict endotoxin parameters. The purchasing standard should require Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C testing confirming endotoxin levels below 0.01 EU/mg. Always confirm that the COA explicitly reports quantitative endotoxin test results rather than stating 'not tested'.

Item 5: Lyophilization Quality, Vial Format, and Fill Mass

The physical state of the lyophilized cake indicates the precision of the freeze-drying process and moisture control. A high-quality peptide cake should appear as a uniform, white to off-white solid at the base of the vial. Visual evidence of collapse, discoloration, or liquid formation suggests moisture contamination or incomplete lyophilization, which drastically accelerates peptide hydrolysis.

In addition, labs must audit fill mass uniformity. Standard research packaging typically supplies 2 mg or 5 mg quantities per vial. Accurate analytical work requires consistent mass distribution across all vials in a batch. When preparing working solutions, investigators should consult a precise reconstitution calculator to determine appropriate volume ratios for target working concentrations using laboratory-grade solvents like sterile bacteriostatic water.

Item 6: Comparative Class Analysis: GHRH Analogs & Secretagogues

When designing protocols investigating the somatotropic axis, researchers often evaluate CJC-1295 (No DAC) alongside related GHRH analogs and growth hormone secretagogues (GHS). Understanding the structural and pharmacokinetic differences across these research compounds is critical when selecting reagents for comparative tissue repair research or endocrine pathway studies.

Preclinical models demonstrate distinct profiles across these agents. While CJC-1295 (No DAC) offers a modified half-life compared to native GHRH, Sermorelin represents the native 1-29 sequence with rapid baseline clearance. Conversely, CJC-1295 DAC includes a bioconjugation site that extends systemic half-life via albumin binding. For ghrelin-receptor targeted signaling, investigators frequently contrast GHRH analogs with selective ghrelin receptor agonists like Ipamorelin. Exploring the broader scope of GHRH research peptides helps labs select the precise ligand required for their specific physiological endpoint.

Item 7: Cold-Chain Logistics, Vendor Compliance, and PX1 Quality Standards

The final criteria on the procurement checklist involve logistical integrity and vendor reliability. Peptides degraded by temperature excursions during transit lose primary structure integrity. Premium suppliers utilize temperature-controlled packaging and rapid shipping workflows to minimize environmental exposure.

PX1 Research addresses every point on the lab procurement checklist through an integrated quality assurance process:

- **USA Manufacturing & ISO Facilities:** Standardized production under strict analytical protocols.

- **HPLC/MS Purity Guarantee:** Every lot verified at ≥98.0% purity with full analytical spectra.

- **Lot-Specific COA Assurance:** Direct access to independent third-party lab documentation.

- **Endotoxin Tested:** Verified safe for cellular and animal model systems.

- **Rapid Fulfillment:** Ships directly from California and Arizona facilities, with same-day dispatch for orders placed Monday through Friday before cut-off times.

For institutions establishing recurring supply lines or volume procurement, PX1 provides structured wholesale lab accounts to maintain batch consistency across long-term research initiatives.